



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2021

**Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma:
Results from the final analysis of the randomized phase 2 Basal Cell
Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months**

Dummer, Reinhard ; Lear, John T ; Guminski, Alex ; Leow, Liang Joo ; Squittieri, Nicholas ; Migden,
Michael

DOI: <https://doi.org/10.1016/j.jaad.2020.08.042>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-194673>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

Originally published at:

Dummer, Reinhard; Lear, John T; Guminski, Alex; Leow, Liang Joo; Squittieri, Nicholas; Migden, Michael (2021). Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months. *Journal of the American Academy of Dermatology*, 84(4):1162-1164.

DOI: <https://doi.org/10.1016/j.jaad.2020.08.042>

RESEARCH LETTER

Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months

To the Editor: Basal cell carcinoma (BCC) is the most common cancer worldwide.¹ Major histologic subtypes of BCC include nonaggressive (nodular and superficial) and aggressive forms (morpheaform, infiltrative, micronodular, and basosquamous).¹ Locally advanced BCC and metastatic BCC can cause extensive tissue destruction, limiting effective treatment options.¹

Sonidegib, a Hedgehog pathway inhibitor selectively targeting Smoothed, is approved in the United States for the treatment of adult patients with recurrent locally advanced BCC after surgery or radiation therapy or those who are not candidates for surgery or radiation therapy.² Here we examine the long-term efficacy of sonidegib 200 and 800 mg once daily across histologic subtypes of BCC at 42 months.

Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT; NCT01327053) is an international, randomized, double-blind, phase 2 study with patients randomized 1:2 to sonidegib 200 or 800 mg once daily. The primary endpoint was objective response rate (ORR) by central review. Key secondary endpoints included duration of response, time to tumor response, progression-free survival, and overall survival. Tumor evaluations and ORR were assessed per BCC-modified Response Criteria In Solid Tumors (mRECIST) for locally advanced BCC and RECIST version 1.1 for metastatic BCC.³ Tumor evaluations were conducted at baseline, weeks 5 and 9, every 8 weeks during the first year, and every 12 weeks thereafter.

Overall, 230 patients enrolled; 36 (15.7%) with metastatic BCC and 194 (84.3%) with locally advanced BCC (aggressive, 112 of 194 [57.7%]; nonaggressive, 82 of 194 [42.3%]). The ORRs at 42 months for patients with aggressive and nonaggressive locally advanced BCC were 59.5% (22 of 37) and 51.7% (15 of 29) for 200 mg and 45.3% (34 of 75)

and 47.2% (25 of 53) for 800 mg, respectively. Among patients with metastatic BCC, ORRs were 7.7% (200 mg) and 17.4% (800 mg).

Highest ORRs were in infiltrative (200 mg, 51.6% [16 of 31]; 800 mg, 36.8% [21 of 57]) and morpheaform (200 mg, 50.0% [3 of 6]; 800 mg, 75.0% [6 of 8]) for aggressive subtypes. Approximately 50% of patients with nonaggressive subtypes in each group achieved objective response (Table I). Median duration of response for patients with nodular subtype was not estimable and was 15.7 months (95% confidence interval, 7.4-26.4 months) for 200 mg and 800 mg, respectively (Table II).

Patients with infiltrative locally advanced BCC receiving 800 mg had a longer median progression-free survival but lower ORR vs patients receiving 200 mg, highlighting that this analysis was underpowered to determine differences between treatment groups within a histologic subtype.

Subtypes with more enrolled patients generally demonstrated ORRs similar to those observed in the entire population, suggesting a consistent response to sonidegib across histologic subtypes. Comparably, BCC histopathologic subtype did not appear to influence overall tumor response to vismodegib over 12 to 24 weeks.⁴

Limitations of this study include the small patient sample size and the exclusion of patients with recurrent disease previously treated with a Hedgehog inhibitor.

The 42-month results from the BOLT study demonstrate long-term positive responses for patients with aggressive and nonaggressive histologic subtypes of advanced BCC. These results are similar to those at 6 and 30 months.^{3,5} Future investigations may clarify whether differences within subtypes remain consistent in larger populations.

The authors thank the patients and their families; the study investigators, their clinical teams, and the study site staff; and the members of the study committees. The authors also thank the Novartis BOLT clinical study team, Yi Wu of Novartis for statistical support, the independent data monitoring committee (Mark R. Pittelkow, Jürgen C. Becker, and Stephen L. George), the efficacy independent review (Vernon K. Sondak, James Grichnik, and Lawrence Schwartz), and the muscle safety review and adjudication committee (Robert S. Rosenson, Vinay Chaudhry, and Paul D. Thompson). Medical writing and editorial assistance were provided by Leila Strickland, PhD; and Sherri Damlo, BA, of MedThink SciCom; and Zehra Gundogan, VMD, of AlphaBioCom, LLC, under the direction of the

Table I. Best overall response in patients with aggressive and nonaggressive subtypes of advanced basal cell carcinoma treated with sonidegib

Best overall response*	Sonidegib 200 mg				Sonidegib 800 mg			
	Aggressive		Nonaggressive		Aggressive		Nonaggressive	
	Infiltrative (n = 31)	Morpheaform (n = 6)	Nodular (n = 28)	Superficial (n = 10)	Infiltrative (n = 57)	Morpheaform (n = 8)	Nodular (n = 42)	Superficial (n = 25)
Complete response	1 (3.2)	0	2 (7.1)	0	0	1 (12.5)	0	1 (4.0)
Partial response	15 (48.4)	3 (50.0)	11 (39.3)	5 (50.0)	21 (36.8)	5 (62.5)	20 (47.6)	12 (48.0)
Stable disease	12 (38.7)	2 (33.3)	12 (42.9)	5 (50.0)	24 (42.1)	2 (25.0)	17 (40.5)	8 (32.0)
Progressive disease	1 (3.2)	0	0	0	1 (1.8)	0	0	0
Unknown	2 (6.5)	1 (16.7)	3 (10.7)	0	11 (19.3)	0	5 (11.9)	4 (16.0)
Overall response rate†	16 (51.6)	3 (50.0)	13 (46.4)	5 (50.0)	21 (36.8)	6 (75.0)	20 (47.6)	13 (52.0)

*Data are shown as number (%).

†Calculated as complete response + partial response.

Table II. Response characteristics in patients with histologic subtypes of advanced basal cell carcinoma

Characteristic*	Sonidegib 200 mg	Sonidegib 800 mg
TTR, mo		
Infiltrative	4.7 (1.9-6.6)	3.7 (1.9-5.5)
Morpheaform	3.7 (1.2-5.7)	3.7 (1.3-5.6)
Nodular	3.9 (2.1-4.2)	3.8 (1.9-7.4)
Superficial	5.6 (1.9-9.3)	3.9 (1.8-5.6)
DOR, mo		
Infiltrative	12.9 (NE)	23.7 (NE)
Morpheaform	NE	NE
Nodular	NE	15.7 (7.4-26.4)
Superficial	NE	29.6 (NE)
PFS, mo		
Infiltrative	16.9 (11.0-39.6)	29.3 (NE)
Morpheaform	NE	18.3 (NE)
Nodular	24.7 (NE)	19.2 (13.2-30.5)
Superficial	NE	24.9 (NE)

DOR, Duration of response; NE, not estimable; PFS, progression-free survival; TTR, time to tumor response.

*Data are presented as the median (95% confidence interval).

authors and funded by Sun Pharmaceutical Industries, Inc. They have nothing to disclose.

Reinhard Dummer, MD,^a John T. Lear, MD,^b Alex Guminski, MD, PhD,^c Liang Joo Leow, MBBS, MPH&TM,^{d,e,f} Nicholas Squitieri, MD,^g and Michael Migden, MD^b

From the Department of Dermatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland^d; the Department of Dermatology, Salford Royal National Health Service Foundation Trust, Salford, United Kingdom^b; the Department of Oncology, Royal North Shore Hospital, St Leonards, New South Wales^c; the Department of Dermatology, St. Vincent's Private Hospital,^d St Vincent's Clinical School, University of New

South Wales,^e and St Vincent's & Mater Clinical School, University of Notre Dame Australia, Sydney, New South Wales, Australia^f; Medical Affairs Oncology, Sun Pharmaceutical Industries, Inc, Princeton, New Jersey^g; and the Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States.^b

Funding sources: This work was supported by Sun Pharmaceutical Industries, Inc.

Conflicts of interest: Dr Dummer has received research funding from Bristol-Myers Squibb, MSD, Novartis Pharmaceuticals Corporation, Roche, and GlaxoSmithKline; and has served as a consultant or participated on an advisory board for Amgen; Bristol-Myers Squibb; MSD; Novartis Pharmaceuticals Corporation; Roche; GlaxoSmithKline; Sun Pharmaceutical Industries, Inc.; and Takeda. Dr Lear has served as a consultant or speaker for and received honoraria from Novartis Pharmaceuticals Corporation and travel support from Sun Pharmaceutical Industries, Inc. Dr Guminski has participated on advisory boards for Bristol-Myers Squibb, Pfizer, and Sanofi; received honoraria from Novartis Pharmaceuticals Corporation; and received travel support from Astellas and Bristol-Myers Squibb. Author Leow has participated on an advisory board for and received honoraria from Novartis Pharmaceuticals Corporation and has received travel support from Eli Lilly and Company; Janssen Pharmaceuticals; and Sun Pharmaceutical Industries, Inc. Dr Squitieri is an employee of Sun Pharmaceutical Industries, Inc. Dr Migden has participated on advisory boards and received honoraria from Eli Lilly and Company, Genentech Inc, Novartis Pharmaceuticals Corporation, and Regeneron;

and has received consulting fees from Sun Pharmaceutical Industries, Inc.

IRB approval status: The study protocol, amendments, and patient-informed consent were approved by individual Institutional Review Boards at each participating study center.

Correspondence and reprint requests to: Reinhard Dummer, MD, Department of Dermatology, University Hospital Zürich, University of Zürich, Gloriastrasse 31, 8091 Zürich, Switzerland

E-mail: reinhard.dummer@usz.ch

REFERENCES

1. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. *Yale J Biol Med.* 2015;88:167-179.
2. Odomzo (sonidegib capsules). Full prescribing information. Sun Pharmaceutical Industries, Inc., Cranbury, NJ.
3. Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. *Lancet Oncol.* 2015; 16:716-728.
4. Fosko SW, Chu MB, Armbrecht E, et al. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial. *J Am Acad Dermatol.* 2020;82(4): 946-954.
5. Lear J, Migden MR, Lewis K, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. *J Eur Acad Dermatol Venereol.* 2018;32:372-381.

<https://doi.org/10.1016/j.jaad.2020.08.042>